{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:22:17Z","timestamp":1787696537367,"version":"build-2784847793"},"reference-count":38,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T00:00:00Z","timestamp":1587945600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Fundamemntal Clinical Pharma"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vitiligo is a common depigmenting disorder ensuing the loss of epidermal melanocytes. It is a multifactorial disease with immunological, genetic and environmental factors including drug exposure. The purpose of the study was to investigate the drugs and therapeutic subclasses associated with vitiligo occurrence reported in VigiBase<jats:sup>\u00ae<\/jats:sup>, the WHO pharmacovigilance database. A case\/non\u2010case study was carried out by defining cases as vitiligo reports and non\u2010cases as all other reports. The reporting odds ratio (ROR) was calculated for the \u2018suspected\u2019 drugs and drug classes according to ATC level 4. During the study period, 741 cases of vitiligo were registered. Mean age was 49\u00a0\u00b1\u00a020\u00a0years. The disproportionality analysis showed an association between vitiligo and pembrolizumab (ROR 116.9, 95% Confidence Interval (CI) 94.8, 144.3), nivolumab (ROR 22.6, 95% CI 15.8, 32.4), ipilimumab (ROR 41.7, 95% CI 25.0, 69.7), imiquimod (ROR 152.8, 95% CI 103.0, 226.7), adalimumab (ROR 3.8, 95% CI 2.5,5.8), infliximab (ROR 2.6, 95% CI 1.65, 4.01), alemtuzumab (ROR 27.8, 95% CI 17.6, 43.9), and ustekinumab (ROR 9.3, 95% CI 5.6, 15.6). Concerning the pharmacological classes ATC level 4, a significant association was found with monoclonal antibodies, interferons, selective immunosuppressants, TNF\u2010alpha inhibitors, interleukin inhibitors, and topical antivirals. This study confirmed the expected associations between vitiligo and immune checkpoint inhibitors and strengthened the emerging signal about the association between vitiligo and imiquimod, TNF\u2010alpha inhibitors and interferons. New signals were shown with selective immunosuppressants including alemtuzumab and interleukin inhibitors.<\/jats:p>","DOI":"10.1111\/fcp.12558","type":"journal-article","created":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T17:54:45Z","timestamp":1586022885000},"page":"736-742","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Drug\u2010induced vitiligo: a case\/non\u2010case study in Vigibase<sup>\u00ae<\/sup>, the WHO pharmacovigilance database"],"prefix":"10.1111","volume":"34","author":[{"given":"Norah","family":"Anthony","sequence":"first","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Bourneau\u2010martin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ghamrawi","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Lagarce","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Babin","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3738-5998","authenticated-orcid":false,"given":"Marie","family":"Briet","sequence":"additional","affiliation":[{"name":"Service de Pharmacologie\u2010Toxicologie et Pharmacovigilance Centre hospitalo\u2010Universitaire d\u2019Angers 4 rue larrey 49100 Angers France"},{"name":"Universit\u00e9 d\u2019Angers Angers France"},{"name":"Laboratoire MitoVasc UMR CNRS 6214 INSERM 1083 Angers France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,4,27]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0804388"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60763-7"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12166"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2013.10.010"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.32"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920010791526105"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omz016"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13867"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2177\/jsci.40.83"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0146-y"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/009286150804200501"},{"key":"e_1_2_7_13_1","unstructured":"WHO Collaboration Centre for Drug Statistics Methodology and Norwegian Institute of Public Health.Guidelines for ATC classification and DDD assignment.2019.https:\/\/www.whocc.no\/filearchive\/publications\/2019_guidelines_web.pdf. Accessed July 24 2019."},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02799-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1742"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12264"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-019-00875-6"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3319"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2019.03.015"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.4.454"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2007.02520.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2015.27.5.620"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12002"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2013.09.158"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12917"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2017.29.6.826"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13498"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20142887"},{"key":"e_1_2_7_29_1","first-page":"217","article-title":"New\u2010onset vitiligo during long\u2010term, stable infliximab treatment of pityriasis rubra pilaris","volume":"12","author":"Mattox A.R.","year":"2013","journal-title":"J. Drugs Dermatol."},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14016"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.012"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0749.2002.1o049.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246208"},{"key":"e_1_2_7_34_1","first-page":"289","article-title":"Vitiligo associated with alpha\u2010interferon in a patient with chronic active hepatitis C","volume":"60","author":"Nouri K.","year":"1997","journal-title":"Cutis"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/387140"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.12234"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2008.02719.x"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13759"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006648"}],"container-title":["Fundamental &amp; Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ffcp.12558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/fcp.12558","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/fcp.12558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T14:16:27Z","timestamp":1737555387000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/fcp.12558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,27]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["10.1111\/fcp.12558"],"URL":"https:\/\/doi.org\/10.1111\/fcp.12558","archive":["Portico"],"relation":{},"ISSN":["0767-3981","1472-8206"],"issn-type":[{"value":"0767-3981","type":"print"},{"value":"1472-8206","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,27]]},"assertion":[{"value":"2019-10-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}